They reduce hunger, slow digestion, and support calorie control
Safety and Tolerability Under Research Conditions Commonly monitored signals include GIrelated events (e.g., nausea), changes in heart rate, and laboratory chemistry panels
Retatrutide (LY-3437943) is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors, three pathways that regulate appetite, metabolism, and fat oxidation
Julie Gralow, chief medical officer of ASCO
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
GLP-1 / GIP (active ingredient tirzepatide) medication has been FDA approved under the name Zepbound* for weight loss